UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 36

Sortiert nach

Phase II Study of Belagenpumatucel-L, a Transforming Growth Factor Beta-2 Antisense Gene-Modified Allogeneic Tumor Cell Vaccine in Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2006-10, Vol.24 (29), p.4721-4730

2006

Volltextzugriff (PDF)

Lipopolysaccharides from Distinct Pathogens Induce Different Classes of Immune Responses In Vivo

The Journal of immunology (1950), 2001-11, Vol.167 (9), p.5067-5076

2001

Volltextzugriff (PDF)

Summary of bi-shRNAfurin/GM-CSF Augmented Autologous Tumor Cell Immunotherapy (FANG™) in Advanced Cancer of the Liver

Oncology, 2014, Vol.87 (1), p.21-29

2014

Volltextzugriff (PDF)

Phase I Trial of “bi-shRNAifurin/GMCSF DNA/Autologous Tumor Cell” Vaccine (FANG) in Advanced Cancer

Molecular therapy, 2012-03, Vol.20 (3), p.679-686

2012

Volltextzugriff (PDF)

Preclinical Justification of pbi-shRNA EWS/FLI1 Lipoplex (LPX) Treatment for Ewing's Sarcoma

Molecular therapy, 2016-08, Vol.24 (8), p.1412-1422

2016

Volltextzugriff (PDF)

Phase II study of Vigil® DNA engineered immunotherapy as maintenance in advanced stage ovarian cancer

Gynecologic oncology, 2016-12, Vol.143 (3), p.504-510

2016

Volltextzugriff (PDF)

Phase I trial of "bi-shRNAi(furin)/GMCSF DNA/autologous tumor cell" vaccine (FANG) in advanced cancer

Molecular therapy, 2012-03, Vol.20 (3), p.679

2012

Volltextzugriff (PDF)

Summary of bi-shRNA/GM-CSF augmented autologous tumor cell immunotherapy (FANG™) in advanced cancer of the liver

Oncology, 2014-01, Vol.87 (1), p.21-29

2014

Volltextzugriff (PDF)

Phase 1 Trial of Bi-shRNA STMN1 BIV in Refractory Cancer

Molecular therapy, 2015-06, Vol.23 (6), p.1123-1130

2015

Volltextzugriff (PDF)

Phase I Trial of TGF-β2 Antisense GM-CSF Gene-Modified Autologous Tumor Cell (TAG) Vaccine

Clinical cancer research, 2011, Vol.17 (1), p.183-192

2011

Volltextzugriff (PDF)

Phase I trial of TGF-beta 2 antisense GM-CSF gene-modified autologous tumor cell (TAG) vaccine

Clinical cancer research, 2011-01, Vol.17 (1), p.183-192

2011

Volltextzugriff (PDF)

Pilot Trial of FANG Immunotherapy in Ewing's Sarcoma super(MT)Open

Molecular therapy, 2015-06, Vol.23 (6), p.1103-1109

2015

Volltextzugriff (PDF)

Survival effect of bi-shRNA furin /GMCSF DNA-based immunotherapy (FANG) in 123 advanced cancer patients to α-interferon-ELISPTOT response

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.3077-3077

2014

Volltextzugriff (PDF)

Pilot trial of vigil immunotherapy in Ewing’s sarcoma

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.10522-10522

2015

Volltextzugriff (PDF)

In vivo safety and antitumor efficacy of bifunctional small hairpin RNAs specific for the human Stathmin 1 oncoprotein

DNA and cell biology, 2011-09, Vol.30 (9), p.715

2011

Volltextzugriff (PDF)

Follow-up of bi-shRNA furin / GM-CSF Engineered Autologous Tumor Cell (EATC) Immunotherapy Vigil® in patients with advanced melanoma

Biomedical genetics and genomics, 2016, Vol.1 (4)

2016

Volltextzugriff (PDF)

Bifunctional short hairpin RNA (bi-shRNA): design and pathway to clinical application

Methods in molecular biology (Clifton, N.J.), 2013, Vol.942, p.259

2013

Volltextzugriff (PDF)

Activation of microglia: A neuroinflammatory role for CAP37

Glia, 2003-01, Vol.41 (1), p.64-72

2003

Volltextzugriff (PDF)

CAP37, a neutrophil-derived inflammatory mediator, augments leukocyte adhesion to endothelial monolayers

Microvascular research, 2003-07, Vol.66 (1), p.38-48

2003

Volltextzugriff (PDF)

CAP37, a Novel Inflammatory Mediator : Its Expression in Endothelial Cells and Localization to Atherosclerotic Lesions

The American journal of pathology, 2002-03, Vol.160 (3), p.841-848

2002

Volltextzugriff (PDF)

Corneal Expression of the Inflammatory Mediator CAP37

Investigative ophthalmology & visual science, 2002-05, Vol.43 (5), p.1414-1421

2002

Volltextzugriff (PDF)

51. Clinical Study of Personalized Therapeutics Based on Genomic/Proteomic Profiling

Molecular therapy, 2006-05, Vol.13 (S1), p.S21-S22

2006

Volltextzugriff (PDF)

Expression of CAP37, a Novel Inflammatory Mediator, in Alzheimer's Disease

Neurobiology of aging, 1996-10, Vol.17 (5), p.753-759

Pereira, H

1996

Volltextzugriff (PDF)

Functional modulation of smooth muscle cells by the inflammatory mediator CAP37

Microvascular research, 2004-03, Vol.67 (2), p.168-181

2004

Volltextzugriff (PDF)

1104. Phase II Study of Lucanix™ a Transforming Growth Factor β2 (TGF-β2) Antisense Gene Modified Allogeneic Tumor Cell Vaccine in Non Small Cell Lung Cancer (NSCLC)

Molecular therapy, 2006-05, Vol.13 (S1), p.S424-S425

2006

Volltextzugriff (PDF)

1 – 25 von 36

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(31)
Mit Volltextzugriff
(33)

Publikationsform

Sprache

Englisch
(36)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Phase II Study of Belagenpumatucel-L, a Transforming Growth Factor Beta-2 Antisense Gene-Modified Allogeneic Tumor Cell Vaccine in Non–Small-Cell Lung Cancer

Lipopolysaccharides from Distinct Pathogens Induce Different Classes of Immune Responses In Vivo

Summary of bi-shRNAfurin/GM-CSF Augmented Autologous Tumor Cell Immunotherapy (FANG™) in Advanced Cancer of the Liver

Phase I Trial of “bi-shRNAifurin/GMCSF DNA/Autologous Tumor Cell” Vaccine (FANG) in Advanced Cancer

Preclinical Justification of pbi-shRNA EWS/FLI1 Lipoplex (LPX) Treatment for Ewing's Sarcoma

Phase II study of Vigil® DNA engineered immunotherapy as maintenance in advanced stage ovarian cancer

Phase I trial of "bi-shRNAi(furin)/GMCSF DNA/autologous tumor cell" vaccine (FANG) in advanced cancer

Summary of bi-shRNA/GM-CSF augmented autologous tumor cell immunotherapy (FANG™) in advanced cancer of the liver

Phase 1 Trial of Bi-shRNA STMN1 BIV in Refractory Cancer

Phase I Trial of TGF-β2 Antisense GM-CSF Gene-Modified Autologous Tumor Cell (TAG) Vaccine

Phase I trial of TGF-beta 2 antisense GM-CSF gene-modified autologous tumor cell (TAG) vaccine

Pilot Trial of FANG Immunotherapy in Ewing's Sarcoma super(MT)Open

Survival effect of bi-shRNA furin /GMCSF DNA-based immunotherapy (FANG) in 123 advanced cancer patients to α-interferon-ELISPTOT response

Pilot trial of vigil immunotherapy in Ewing’s sarcoma

In vivo safety and antitumor efficacy of bifunctional small hairpin RNAs specific for the human Stathmin 1 oncoprotein

Follow-up of bi-shRNA furin / GM-CSF Engineered Autologous Tumor Cell (EATC) Immunotherapy Vigil® in patients with advanced melanoma

Bifunctional short hairpin RNA (bi-shRNA): design and pathway to clinical application

Activation of microglia: A neuroinflammatory role for CAP37

CAP37, a neutrophil-derived inflammatory mediator, augments leukocyte adhesion to endothelial monolayers

CAP37, a Novel Inflammatory Mediator : Its Expression in Endothelial Cells and Localization to Atherosclerotic Lesions

Corneal Expression of the Inflammatory Mediator CAP37

51. Clinical Study of Personalized Therapeutics Based on Genomic/Proteomic Profiling

Expression of CAP37, a Novel Inflammatory Mediator, in Alzheimer's Disease

Functional modulation of smooth muscle cells by the inflammatory mediator CAP37

1104. Phase II Study of Lucanix™ a Transforming Growth Factor β2 (TGF-β2) Antisense Gene Modified Allogeneic Tumor Cell Vaccine in Non Small Cell Lung Cancer (NSCLC)

Suchergebnisse filtern